- Epoetin-Alfa
- Epoetin-Beta
- Epoetin-Delta
- Epoetin-Omega
- Darbepoetin-Alfa
- Others
Erythropoietin Stimulating Agents Market size was valued at USD 8.930 million in 2022 and is expected to reach USD 15.909 million by 2029, at a CAGR of 8.6% during the forecast period 2023-2029. Erythropoietin is a hormone produced by kidney that enables stimulate production of RBC. Erythropoietin stimulating agents are the drugs used to stimulate the bone marrow to enhance the production of red blood cells. The drugs are commonly used in the treatment of anemia due to end stage renal disease (ESRD), major surgeries, chemotherapy, and HIV/AIDS leads to decrease the need of blood transfusion. Erythropoiesis is the name given to the process of red blood cell production. Erythropoiesis is a process that occurs in the bone marrow. Erythropoiesis-stimulating agents are substances that promote the production of red blood cells. These are recombinant versions of the hormone erythropoietin, which is produced naturally by the kidneys and is responsible for promoting red blood cell formation in the bone marrow. For the treatment of anaemia, erythropoiesis-stimulating drugs are indicated. Hemoglobin is a protein found in red blood cells that transports oxygen throughout the body. Anemia occurs when the body does not obtain enough oxygen due to a low number of red blood cells. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Erythropoietin Stimulating Agents Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Erythropoietin Stimulating Agents Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The global market for erythropoiesis-stimulating drugs is growing due to the rising frequency of anaemia cases around the world. Furthermore, increased knowledge of erythropoiesis-stimulating agent therapy is fueling market expansion. Because of the expanding prevalence of chronic kidney disease and cancer, as well as the growing desire for less expensive erythropoietin medications, the demand for erythropoiesis-stimulating substances is fast increasing. Researchers and pharmaceutical companies are working to produce new erythropoietin medicines. However, strict regulatory criteria and side effects associated with erythropoiesis-stimulating drugs, such as hypersensitivity, hypertension, seizures, or convulsions, are limiting market expansion. Rise in prevalence of anemia, ESRD, HIV, and cancer around the globe is witnessed to increased demand for global erythropoietin stimulating agents market. Moreover, rise in R&D for innovation of newer drugs, entry of bio-similar and generics into market due to expiration of patents are expected to increase in the adoption of low-cost drugs in developing countries, and rise in awareness about the benefits erythropoietin drugs are anticipated to propel the erythropoietin stimulating agents market over the forecast period. However, stringent regulations for the product approval, adverse effects associated with drugs, and high cost of patented drugs are impede the growth of erythropoietin stimulating agents market.
Erythropoietin Stimulating Agents Market size was valued at USD 8.930 million in 2022 and is expected to reach USD 15.909 million by 2029.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
rising frequency of anaemia cases around the world
Europe is the fastest-growing for erythropoietin stimulating agents market
1.Executive Summary |
2.Global Erythropoietin Stimulating Agents Market Introduction |
2.1.Global Erythropoietin Stimulating Agents Market - Taxonomy |
2.2.Global Erythropoietin Stimulating Agents Market - Definitions |
2.2.1.Product Type |
2.2.2.Application |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Erythropoietin Stimulating Agents Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Erythropoietin Stimulating Agents Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Erythropoietin Stimulating Agents Market By Product Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Epoetin-Alfa |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Epoetin-Beta |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Epoetin-Delta |
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Epoetin-Omega |
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Darbepoetin-Alfa |
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Erythropoietin Stimulating Agents Market By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Oncology |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Renal Disorders |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Anemia |
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Surgeries |
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Erythropoietin Stimulating Agents Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Erythropoietin Stimulating Agents Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Epoetin-Alfa |
9.1.2.Epoetin-Beta |
9.1.3.Epoetin-Delta |
9.1.4.Epoetin-Omega |
9.1.5.Darbepoetin-Alfa |
9.1.6.Others |
9.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oncology |
9.2.2.Renal Disorders |
9.2.3.Anemia |
9.2.4.Surgeries |
9.2.5.Others |
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Epoetin-Alfa |
10.1.2.Epoetin-Beta |
10.1.3.Epoetin-Delta |
10.1.4.Epoetin-Omega |
10.1.5.Darbepoetin-Alfa |
10.1.6.Others |
10.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oncology |
10.2.2.Renal Disorders |
10.2.3.Anemia |
10.2.4.Surgeries |
10.2.5.Others |
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11.Asia Pacific (APAC) Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Epoetin-Alfa |
11.1.2.Epoetin-Beta |
11.1.3.Epoetin-Delta |
11.1.4.Epoetin-Omega |
11.1.5.Darbepoetin-Alfa |
11.1.6.Others |
11.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oncology |
11.2.2.Renal Disorders |
11.2.3.Anemia |
11.2.4.Surgeries |
11.2.5.Others |
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Epoetin-Alfa |
12.1.2.Epoetin-Beta |
12.1.3.Epoetin-Delta |
12.1.4.Epoetin-Omega |
12.1.5.Darbepoetin-Alfa |
12.1.6.Others |
12.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oncology |
12.2.2.Renal Disorders |
12.2.3.Anemia |
12.2.4.Surgeries |
12.2.5.Others |
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Epoetin-Alfa |
13.1.2.Epoetin-Beta |
13.1.3.Epoetin-Delta |
13.1.4.Epoetin-Omega |
13.1.5.Darbepoetin-Alfa |
13.1.6.Others |
13.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oncology |
13.2.2.Renal Disorders |
13.2.3.Anemia |
13.2.4.Surgeries |
13.2.5.Others |
13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Teva Pharmaceutical Industries Ltd. (Israel) |
14.2.2.Biocon Limited (India) |
14.2.3.Celltrion, Inc. (South Korea) |
14.2.4.Hoffmann La Roche, Ltd. (Switzerland) |
14.2.5.Hospira, Inc. (Pfizer, Inc.) (U.S.) |
14.2.6.Johnson & Johnson Services, Inc. (U.S.) |
14.2.7.Amgen, Inc. (U.S.) |
14.2.8.Dr. Reddy's Laboratories Ltd (India) |
14.2.9.Intas Pharmaceuticals (India) |
14.2.10.3SBio, Inc. (China) |
14.2.11.Kissei Pharmaceuticals Ltd (Japan) |
15. Research Methodology |
16. Appendix and Abbreviations |